Seeking Alpha

Sucampo Pharmaceuticals (SCMP) and its partner Takeda (TKPHF.PK) say AMITIZA has racked up a...

Sucampo Pharmaceuticals (SCMP) and its partner Takeda (TKPHF.PK) say AMITIZA has racked up a third indication as the FDA approves the drug for the treatment of opioid-induced constipation. Cantor Fitzgerald previously said AMITIZA could ultimately prove to be a major catalyst for shares of SCMP which are up a quick 13.6% premarket.
Comments (1)
  • norjud
    , contributor
    Comments (191) | Send Message
     
    Looks like a winner. Takeda needs to go ahead and buy at this low price...ya Dig!
    24 Apr 2013, 11:03 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|